What's new

Human medicines European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta), umeclidinium, Date of authorisation: 20/03/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta), umeclidinium, Date of authorisation: 20/03/2017, Revision: 14, Status: Authorised

Mar 28, 2025 - 14:08
 0
Human medicines European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta), umeclidinium, Date of authorisation: 20/03/2017, Revision: 14, Status: Authorised
Human medicines European public assessment report (EPAR): Rolufta Ellipta (previously Rolufta), umeclidinium, Date of authorisation: 20/03/2017, Revision: 14, Status: Authorised
Read More

Tags:

Previous Article

What diversity means in medtech

Next Article

Prepping for tariffs

Related Posts

PSUSA/00010184/202406

PSUSA/00010184/202406

Feb 13, 2025  0

Human medicines European public assessment report (EPAR): Neupro, rotigotine, Date of authorisation: 15/02/2006, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 19, 2025  0

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 3, 2025  0